Activella - Comprehensive Research Paper

Document Version: 1.0 Last Updated: 2025-12-26 Classification: HRT Research - Combination Estrogen/Progestin Products (Oral) Paper Number: 42 of 76

1. Summary

1.1 Executive Summary

Activella is an oral combination hormone replacement therapy (HRT) containing estradiol and norethindrone acetate (NETA) for postmenopausal women with an intact uterus. It is one of the most widely prescribed oral continuous combined HRT products and is available in generic forms, making it a cost-effective option for menopausal symptom management and osteoporosis prevention.

Key Distinguishing Features:

• Once-daily oral tablet: Convenient administration
• Two strength options: Allows dose titration (1 mg/0.5 mg and 0.5 mg/0.1 mg)
• Generic available: Cost-effective vs. brand-only options
• Continuous combined regimen: Reduces endometrial hyperplasia risk
• Dual indications: Vasomotor symptoms AND osteoporosis prevention

FDA-Approved Indications (in women with intact uterus):

| Indication | 1 mg/0.5 mg | 0.5 mg/0.1 mg | |---

Goal Relevance:

• Manage hot flashes and night sweats for a more comfortable menopause experience
• Improve vaginal health and reduce dryness for enhanced sexual wellness
• Prevent bone loss and maintain bone strength to reduce the risk of osteoporosis
• Achieve hormone balance to alleviate mood swings and irritability during menopause
• Opt for a convenient, once-daily oral medication to manage menopause symptoms effectively
• Choose a cost-effective hormone therapy solution with generic options available

---------|-------------|---------------| | Moderate to severe vasomotor symptoms | Yes | Yes | | Vulvar and vaginal atrophy | Yes | No | | Prevention of postmenopausal osteoporosis | Yes | Yes |

Safety Profile:

• Common (≥5%): Headache, breast pain, back pain, flu syndrome, abdominal pain
• Serious risks: VTE, stroke, MI, breast cancer (class warnings for all E+P products)
• Endometrial hyperplasia: ~1% or less with continuous combined regimen

Current Formulations:

Brand and Generic:

1.2 Chemical and Pharmacological Classification

Estradiol Component:

• Chemical Name: 17β-Estradiol
• Molecular Formula: C₁₈H₂₄O₂
• Molecular Weight: 272.39 g/mol
• CAS Number: 50-28-2
• Class: Bioidentical estrogen

Norethindrone Acetate Component:

• Chemical Name: 17α-Ethinyl-19-nortestosterone acetate
• Molecular Formula: C₂₂H₂₈O₃
• Molecular Weight: 340.46 g/mol
• CAS Number: 51-98-9
• Class: Synthetic progestin (estrane, 1st generation)
• Prodrug: Rapidly converted to norethindrone after oral administration

Product Classification:

• Drug Class: Combination estrogen/progestin HRT
• Delivery System: Oral tablet (film-coated)
• Regimen Type: Continuous combined
• Application Frequency: Once daily

1.3 Historical Background

Development Timeline:

• 1998: Activella (1 mg/0.5 mg) approved by FDA
• 2006: Lower dose (0.5 mg/0.1 mg) approved
• 2002: WHI results impact HRT prescribing patterns
• 2009+: Generic versions become available
• Present: Multiple generic manufacturers; widely prescribed

Manufacturer: Originally Novo Nordisk; now multiple generic manufacturers.

Related Products:

1.4 Clinical Context and Rationale

Why Combination Estrogen/Progestin?

In women with an intact uterus, estrogen alone significantly increases endometrial hyperplasia and cancer risk. Adding norethindrone acetate provides endometrial protection:

Why Oral Route?

Clinical Position:

Activella is appropriate for:

1. Postmenopausal women with intact uterus
2. Moderate to severe vasomotor symptoms
3. Need for osteoporosis prevention
4. Preference for oral administration
5. Cost sensitivity (generic available)

2. Mechanism of Action

2.1 Estradiol Component

Estrogen Receptor Activation:

Estradiol binds to estrogen receptors (ERα and ERβ), which are nuclear transcription factors regulating gene expression.

Mechanism by Target:

2.2 Norethindrone Acetate Component

Prodrug Conversion:

Norethindrone acetate is rapidly and completely deacetylated to norethindrone after oral absorption. All pharmacological activity is from norethindrone.

Progesterone Receptor Agonism:

Receptor Binding Profile:

2.3 Combined Pharmacological Effect

On Endometrium:

Why Continuous Combined?

• Constant progestin opposition to estrogen
• Results in endometrial atrophy
• Reduces breakthrough bleeding (after initial months)
• Eliminates scheduled withdrawal bleeding
• Simplifies regimen vs. sequential

2.4 Pharmacological Effects by System

Thermoregulatory:

• Estradiol stabilizes hypothalamic set point
• Reduces norepinephrine-mediated vasodilation
• Widens thermoneutral zone
• Result: Fewer, less severe hot flashes

Skeletal:

Genitourinary:

Hepatic (First-Pass Effects):

2.5 Progestin Class Considerations

Norethindrone Characteristics:

Conversion to Ethinyl Estradiol:

Norethindrone can be partially converted to ethinyl estradiol (EE) in vivo (~0.35% conversion), contributing minor additional estrogenic effect.

3. Indications and Uses

3.1 FDA-Approved Indications

Activella 1 mg/0.5 mg:

1. Moderate to severe vasomotor symptoms due to menopause
2. Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
3. Prevention of postmenopausal osteoporosis

Activella 0.5 mg/0.1 mg:

1. Moderate to severe vasomotor symptoms due to menopause
2. Prevention of postmenopausal osteoporosis

Note: Lower dose (0.5 mg/0.1 mg) is NOT indicated for vulvar/vaginal atrophy

3.2 Vasomotor Symptoms

Target Population:

• Postmenopausal women with intact uterus
• Moderate to severe hot flashes/night sweats
• Symptoms affecting quality of life

Efficacy:

Dose Selection:

3.3 Vulvar and Vaginal Atrophy

Indication: Only for 1 mg/0.5 mg strength

Target Symptoms:

• Vaginal dryness
• Dyspareunia
• Vaginal itching/irritation

Note: For isolated genitourinary symptoms, local (vaginal) estrogen is often preferred. Systemic HRT addresses both vasomotor AND genitourinary symptoms.

3.4 Osteoporosis Prevention

Indication Criteria:

1. Postmenopausal women at significant osteoporosis risk
2. Non-estrogen medications have been considered
3. Benefits outweigh risks

Risk Factors for Osteoporosis:

• Low body weight
• Family history of osteoporosis
• Personal history of fragility fracture
• Smoking
• Excessive alcohol
• Low calcium/vitamin D intake
• Sedentary lifestyle
• Early menopause

Evidence:

Adjunctive Measures:

3.5 Important Limitations

NOT Indicated For:

4. Dosing and Administration

4.1 Available Strengths

4.2 Standard Dosing

Dosing Principle: Start at lowest effective dose

Administration:

• One tablet once daily
• Same time each day
• With or without food (food may reduce peak but not total absorption)
• Swallow whole; do not crush or chew

4.3 Initiation of Therapy

Starting Activella:

Initial Evaluation:

1. Confirm menopause status
2. Rule out contraindications
3. Baseline mammogram
4. Discuss risks and benefits
5. Pelvic exam if indicated

4.4 Duration of Use

General Guidelines:

When to Consider Discontinuation:

• Symptoms resolved
• New contraindication
• Patient preference
• Duration >5 years (increasing breast cancer risk)

4.5 Missed Dose

4.6 Dose Adjustments

Symptom Control:

Hepatic Impairment:

Renal Impairment:

• No specific dose adjustment required
• Use with caution in severe impairment

5. Pharmacokinetics and Pharmacodynamics

5.1 Absorption

Estradiol:

Norethindrone Acetate → Norethindrone:

5.2 Steady-State Concentrations

At Steady-State:

Time to Steady-State:

• Estradiol: ~1-2 days (short half-life)
• Norethindrone: ~1-2 weeks (accumulation factor)

5.3 Distribution

Estradiol:

Norethindrone:

5.4 Metabolism

Estradiol Metabolism:

Primary CYP Enzymes: CYP3A4, CYP1A2

Norethindrone Metabolism:

CYP3A4 is the primary enzyme for norethindrone metabolism.

5.5 Elimination

Estradiol:

Norethindrone:

5.6 Drug Interactions (Pharmacokinetic)

CYP3A4 Inducers (↓ Both E2 and NETA):

CYP3A4 Inhibitors (↑ Both E2 and NETA):

5.7 Pharmacodynamic Effects

On Endometrium:

On Bone:

6. Side Effects and Safety Profile

6.1 Common Side Effects (≥5%)

Clinical Trial Data (Activella 1 mg/0.5 mg):

6.2 Less Common Side Effects (1-5%)

6.3 Serious Risks (Black Box Warnings)

FDA Black Box Warnings Apply:

Women's Health Initiative (WHI) Data:

Note: WHI studied oral conjugated estrogens + MPA, not Activella specifically

6.4 Venous Thromboembolism

VTE Risk with Oral E+P:

Risk Factors for VTE:

• Personal/family history of VTE
• Obesity (BMI >30)
• Immobility
• Recent surgery
• Thrombophilia
• Smoking
• Age >60

Oral vs. Transdermal:

Oral HRT (including Activella) carries higher VTE risk than transdermal due to first-pass hepatic effects on coagulation proteins.

6.5 Breast Cancer Risk

WHI Findings (E+P):

Activella-Specific Data:

In 1-year trial (1,176 women): 2 new breast cancer cases among 295 women treated with Activella 1 mg/0.5 mg.

Clinical Implications:

• Annual mammography required
• Clinical breast exam at each visit
• Discuss risks with patient
• Consider limiting duration

6.6 Cardiovascular Safety

Stroke:

• WHI: Increased stroke risk with E+P (HR 1.31)
• Risk greater in older women
• Not for stroke prevention

Coronary Heart Disease:

• No cardioprotection demonstrated
• May increase CHD risk, especially if started >10 years post-menopause
• Not indicated for cardiovascular prevention

Blood Pressure:

6.7 Endometrial Safety

Activella Endometrial Hyperplasia Rates:

Bleeding Patterns:

Investigate Abnormal Bleeding:

• Persistent irregular bleeding after 6 months
• Heavy bleeding at any time
• Bleeding after established amenorrhea

6.8 Other Serious Risks

Gallbladder Disease:

• 2-4 fold increased risk of cholecystectomy
• Estrogen increases cholesterol saturation of bile

Ovarian Cancer:

• Small increased risk with HRT use
• Risk may increase with duration

Dementia:

• WHIMS (women ≥65): Increased probable dementia risk with E+P
• Not recommended for cognitive protection

7. Drug Interactions

7.1 CYP3A4 Interactions

Both estradiol and norethindrone are metabolized by CYP3A4.

CYP3A4 Inducers (↓ Hormone Levels):

CYP3A4 Inhibitors (↑ Hormone Levels):

7.2 Specific Drug Interactions

7.3 Effect of Hormones on Other Drugs

Drugs Affected:

7.4 Laboratory Test Interactions

May Affect:

7.5 Interaction Management

High-Risk (Avoid):

• Rifampin
• St. John's Wort

Moderate-Risk (Monitor Closely):

• Antiepileptics (carbamazepine, phenytoin, phenobarbital)
• Lamotrigine (adjust lamotrigine dose)
• HIV medications
• Long-term azole antifungals

Low-Risk (Routine Monitoring):

• Short-course macrolides
• Moderate grapefruit juice
• Most antihypertensives

8. Contraindications and Precautions

8.1 Absolute Contraindications

DO NOT USE Activella in Women With:

8.2 Additional Contraindications

8.3 Precautions and Warnings

Use with Caution in:

8.4 Pre-Treatment Evaluation

Before Starting Activella:

8.5 Reasons to Discontinue

Stop Activella Immediately If:

8.6 Surgical Considerations

Before Surgery:

After Surgery:

• Resume when fully ambulatory
• Consider VTE prophylaxis if continuing

9. Special Populations

9.1 Age Considerations

Women 50-59 (Within 10 Years of Menopause):

Women 60+ or >10 Years Post-Menopause:

9.2 Pregnancy and Breastfeeding

Pregnancy:

Breastfeeding:

Note: Postmenopausal indication makes pregnancy/breastfeeding scenarios rare.

9.3 Hepatic Impairment

Rationale: Oral HRT undergoes extensive hepatic first-pass metabolism.

9.4 Renal Impairment

9.5 Obesity

Important: Oral HRT + obesity = synergistic VTE risk. Transdermal may be safer.

9.6 Cardiovascular Disease Risk

9.7 Thrombophilia and VTE History

9.8 Breast Cancer Risk

10. Monitoring and Follow-Up

10.1 Baseline Monitoring

Before Starting Activella:

10.2 Ongoing Monitoring

Routine Follow-Up:

10.3 Periodic Reassessment

Timing: Every 3-6 months initially; then annually

Purpose:

1. Evaluate continued need
2. Assess symptom control
3. Review side effects
4. Discuss current risks and benefits
5. Consider discontinuation trial

Tapering Attempt:

10.4 Laboratory Monitoring

As Needed:

10.5 Breast Cancer Surveillance

Protocol:

Patient Education:

• Report lumps, discharge, skin changes
• Risk increases with duration of HRT use

10.6 Endometrial Monitoring

With Continuous Combined HRT:

10.7 Counseling Points

What to Tell Patients:

11. Cost and Availability

11.1 Pricing Overview

Average Wholesale Price (AWP) - 2024:

Patient Cost Examples (Monthly):

11.2 Insurance Coverage

Typical Tier Placement:

Coverage Considerations:

11.3 Generic Availability

Status: Full generic availability since ~2009

AB-Rated Generic Manufacturers:

• Teva Pharmaceuticals
• Mylan (Viatris)
• Sandoz
• Amneal
• Other generic manufacturers

Therapeutic Equivalence:

Clinical Recommendation:

Generic substitution is appropriate and cost-effective. No clinically significant differences between brand and generic products.

11.4 Patient Assistance Programs

Novo Nordisk Patient Assistance:

General Resources:

11.5 Cost Comparison with Alternatives

Monthly Cost Comparison (Generic Where Available):

Cost-Effectiveness:

Generic Activella (E2/NETA) is one of the most cost-effective oral continuous combined HRT options due to wide generic availability.

12. Clinical Evidence Summary

12.1 Pivotal Trials

Activella Phase III Program:

12.2 Vasomotor Symptom Efficacy

Hot Flash Reduction:

Severity Impact:

12.3 Bone Density Effects

HOPE Trial Substudy Data:

Dose Response:

12.4 Endometrial Safety

Hyperplasia Rates in Clinical Trials:

Bleeding Patterns:

Interpretation:

The continuous combined regimen effectively protects the endometrium while achieving high rates of amenorrhea by month 12.

12.5 Long-Term Safety Data (WHI Context)

Women's Health Initiative (WHI) CEE/MPA Results (2002):

While Activella uses different components (E2/NETA vs. CEE/MPA), class effects apply:

Key Differences (E2/NETA vs. CEE/MPA):

12.6 Quality of Life Evidence

HOPE Trial Quality of Life Data:

12.7 Real-World Evidence

Observational Studies:

13. Comparison with Alternatives

13.1 Comparison with Other Oral E+P Products

13.2 Activella vs. Prempro

Clinical Considerations:

• Some patients/providers prefer bioidentical E2 (Activella)
• Prempro has more long-term safety data (WHI)
• Both have generic availability and similar costs
• Switching between products is generally straightforward

13.3 Activella vs. Angeliq

When to Consider Angeliq Over Activella:

• Patients with fluid retention
• Mild hypertension (anti-mineralocorticoid effect)
• Androgen-related symptoms (acne, hirsutism)
• Must monitor potassium if on ACE-I, ARB, potassium-sparing diuretics

13.4 Oral vs. Transdermal Comparison

When to Consider Transdermal Over Oral:

13.5 Activella vs. Bijuva

Bijuva Considerations:

• Only FDA-approved E2+P4 combination oral product
• Bioidentical progesterone may have different risk profile
• Limited long-term data
• Higher cost, no generic

13.6 Decision Framework

Choosing Activella:

Choosing Alternative:

14. Storage and Handling

14.1 Storage Requirements

Temperature:

14.2 Packaging and Protection

Protection Requirements:

Packaging:

• Blister packs or bottles
• Child-resistant closures
• Desiccant may be included

14.3 Dispensing Considerations

Pharmacist Notes:

14.4 Stability

Shelf Life:

14.5 Disposal

Patient Instructions:

15. Goal Archetype Integration (E2+NETA Combination)

15.1 Primary Goal Alignment

Activella combines bioidentical estradiol (E2) with norethindrone acetate (NETA), a synthetic 19-nortestosterone-derived progestin. This combination offers a cost-effective approach to menopausal management with well-established efficacy data.

15.2 E2+NETA Synergy Profile

Estradiol Contribution:

• Primary estrogen (bioidentical to ovarian production)
• ~5% oral bioavailability due to first-pass metabolism
• Provides 30-50 pg/mL average steady-state levels
• Relieves vasomotor, genitourinary, and bone symptoms

NETA Contribution:

• Synthetic progestin with mild androgenic activity
• Rapidly converted to active norethindrone
• High progesterone receptor affinity (endometrial protection)
• Weak estrogen receptor agonism (~0.35% conversion to ethinyl estradiol)
• Mild androgen receptor activity (may have anabolic bone effects)

Combined Profile:

15.3 When Activella Makes Sense

Ideal Patient Profile:

• Postmenopausal woman with intact uterus
• Moderate to severe vasomotor symptoms requiring treatment
• Need for osteoporosis prevention with HRT
• Preference for oral administration (familiar, convenient)
• Cost sensitivity (generic E2/NETA widely available)
• No significant VTE risk factors
• Age <60 or within 10 years of menopause onset

Specific Scenarios Favoring Activella:

• Insurance-driven formulary constraints (generic availability)
• Patients comfortable with daily oral medication
• Women who previously tolerated norethindrone-containing contraceptives
• Multi-symptom presentation (VMS + bone + genitourinary)

15.4 When to Choose Something Else

16. Age-Stratified Dosing

16.1 Age-Specific Dosing Framework

16.2 Timing Hypothesis Integration

The "Window of Opportunity":

The timing hypothesis posits that HRT initiated within 10 years of menopause onset or before age 60 has a favorable risk-benefit profile, while initiation later carries greater risks.

16.3 Dose Selection by Symptom Severity

16.4 Female-Specific Hormonal Considerations

Perimenopausal Transition:

• Hormone levels fluctuate unpredictably
• May need cyclical progestin rather than continuous combined
• Consider low-dose contraceptive if still at pregnancy risk
• Transition to Activella after confirmed menopause (12 months amenorrhea)

Surgical Menopause (Bilateral Oophorectomy):

• Abrupt hormone loss; often more severe symptoms
• May need higher initial dose (1 mg/0.5 mg)
• Consider earlier transition to HRT (immediately post-surgery if indicated)
• Estrogen-alone acceptable if concurrent hysterectomy

Premature Ovarian Insufficiency (POI, <40 years):

• HRT strongly recommended until average menopause age (~51)
• Higher doses often needed
• Activella can be appropriate; may need 1 mg/0.5 mg
• Monitor bone density closely

17. Drug Interactions - Comprehensive

17.1 Prescription Medication Interactions

CYP3A4 Pathway (Primary Interaction Mechanism):

Both estradiol and NETA are metabolized by CYP3A4, creating significant interaction potential.

17.2 High-Risk Drug Combinations (Avoid)

17.3 Other Compounds (Stacking Considerations)

17.4 Supplements

17.5 Food and Timing Considerations

18. Bloodwork Impact & Monitoring

18.1 Expected Marker Changes

Hepatic Markers (First-Pass Effect):

Lipid Markers:

Hormonal Markers:

Other Markers:

18.2 Monitoring Schedule

18.3 Red Flags in Labs

18.4 Labs + Symptoms Integration

19. Protocol Integration (vs. Bioidentical Alternatives)

19.1 Activella vs. Bioidentical HRT Positioning

Activella contains bioidentical estradiol but a synthetic progestin (NETA). This positions it between fully synthetic products (Prempro) and fully bioidentical products (Bijuva, E2 + Prometrium).

Bioidentical Spectrum:

19.2 Comparative Advantages and Disadvantages

Activella (E2+NETA) vs. Bijuva (E2+P4):

Activella vs. Separate E2 + Prometrium:

Activella vs. Transdermal E2 + Oral Progesterone:

19.3 Clinical Decision Algorithm

START: Postmenopausal woman with intact uterus needing HRT

├─ Elevated VTE risk? (BMI >30, history, thrombophilia family history)
│   └─ YES → Transdermal E2 + oral micronized progesterone
│
├─ Cost a major concern?
│   └─ YES → Generic Activella (E2/NETA) or separate generic E2 + progesterone
│
├─ Strong preference for bioidentical hormones?
│   └─ YES → Bijuva (E2+P4) or separate E2 + Prometrium
│
├─ Mood sensitivity to progestins?
│   └─ YES → E2 + micronized progesterone (P4 has GABA-A benefit)
│
├─ Fluid retention/bloating concern?
│   └─ YES → Angeliq (E2 + drospirenone) - anti-mineralocorticoid
│
├─ Needs convenience, no VTE risk factors, cost-conscious?
│   └─ YES → Activella (E2/NETA) - excellent choice
│
└─ Default → Start with lowest dose Activella (0.5/0.1); titrate as needed

19.4 Switching Between Products

From Activella to Bioidentical (E2 + Prometrium):

• Switch can be made directly without washout
• Monitor for bleeding changes during transition
• P4 should be taken at bedtime (sedative effect)

From Activella to Transdermal (Risk Reduction):

• Apply patch after stopping Activella (no washout needed)
• Transdermal E2 has ~20% bioavailability vs oral ~5%
• Start with lower patch dose equivalent

From Bioidentical to Activella (Cost Reduction):

• NETA has different receptor profile than P4
• Monitor for mood changes, breast tenderness
• Counsel that progestogen is no longer bioidentical

19.5 Integration with Health Pillars

20. References

15.1 Prescribing Information

1. Activella (estradiol/norethindrone acetate) tablets prescribing information. Novo Nordisk Inc. Most recent revision.

2. Mimvey (estradiol/norethindrone acetate) tablets prescribing information. Allergan. Most recent revision.

15.2 Clinical Guidelines

3. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.

4. ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202-216. (Reaffirmed 2018)

5. Endocrine Society Clinical Practice Guideline: Treatment of Symptoms of the Menopause. J Clin Endocrinol Metab. 2015;100(11):3975-4011.

15.3 Major Clinical Trials

6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.

7. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287(20):2668-2676.

8. HOPE Study (Women's Health, Osteoporosis, Progestin, Estrogen). Multiple publications evaluating low-dose hormone therapy.

15.4 Safety and Pharmacokinetics

9. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845.

10. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111.

15.5 Progestin Pharmacology

11. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34(2):171-208.

12. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3-63.

15.6 Regulatory Documents

13. FDA Drug Approval Package: Activella NDA 020982. U.S. Food and Drug Administration. 1998.

14. FDA Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms — Recommendations for Clinical Evaluation. January 2003.

15.7 Cost and Access Resources

15. RED BOOK Online. IBM Micromedex. (AWP pricing data)

16. GoodRx drug pricing. https://www.goodrx.com

17. Novo Nordisk Patient Assistance Programs. https://www.novonordisk-us.com

15.8 Patient Resources

18. The North American Menopause Society. https://www.menopause.org

19. American College of Obstetricians and Gynecologists Patient Education. https://www.acog.org/patient-resources

20. FDA MedWatch Safety Information. https://www.fda.gov/safety/medwatch

15.9 Additional References

21. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.

22. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.

23. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231.

Document Completion: 2025-12-26 Status: PAPER 42 OF 76 COMPLETE Next Paper: #43 - Angeliq (Estradiol/Drospirenone)